12:14 PM EST - Clearmind Medicine : Announced it has completed a highly constructive Pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration to discuss the development of the Company’s MEAI- based proprietary compound CMND-100. CMND-100, Clearmind’s lead product that is based on MEAI, a novel psychoactive compound, exerts a significant reduced desire to consume alcoholic beverages, and the company is developing it as a candidate therapy for the treatment of Alcohol Use Disorder. Clearmind Medicine
shares C.CMND are trading unchanged at $0.38.
